Terminal Illness
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Bausch HealthQUEBEC, Quebec, Canada
2 programs2
SC MethylnaltrexonePhase 31 trial
SC MethylnaltrexonePhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Bausch HealthSC Methylnaltrexone
Bausch HealthSC Methylnaltrexone
Forte BiosciencesFamily Talk Intervention
Clinical Trials (3)
Total enrollment: 516 patients across 3 trials
Open-Label Treatment Extension of Protocol MNTX 302
Start: Mar 2004Est. completion: Jan 200689 patients
Phase 3Completed
Open-Label Treatment Extension of Protocol MNTX 301
Start: Feb 2003Est. completion: Feb 200527 patients
Phase 3Completed
Family Talk Intervention in the Context of Specialised Palliative Home Care
Start: Apr 2022Est. completion: Dec 2024400 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.